BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32667737)

  • 21. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.
    Pulitzer MP; Horna P; Almeida J
    Cytometry B Clin Cytom; 2021 Mar; 100(2):132-138. PubMed ID: 32516521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
    Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
    J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sézary syndrome originates from heavily mutated hematopoietic progenitors.
    Harro CM; Sprenger KB; Chaurio RA; Powers JJ; Innamarato P; Anadon CM; Zhang Y; Biswas S; Mandal G; Mine JA; Cortina C; Nagy MZ; Martin AL; Handley KF; Borjas GJ; Chen PL; Pinilla-Ibarz J; Sokol L; Yu X; Conejo-Garcia JR
    Blood Adv; 2023 Sep; 7(18):5586-5602. PubMed ID: 37531660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
    Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
    J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
    Olsen E; Vonderheid E; Pimpinelli N; Willemze R; Kim Y; Knobler R; Zackheim H; Duvic M; Estrach T; Lamberg S; Wood G; Dummer R; Ranki A; Burg G; Heald P; Pittelkow M; Bernengo MG; Sterry W; Laroche L; Trautinger F; Whittaker S;
    Blood; 2007 Sep; 110(6):1713-22. PubMed ID: 17540844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.
    Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H
    J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
    Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
    Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
    Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
    J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides.
    Yazıcı S; Bülbül Başkan E; Budak F; Oral B; Adim ŞB; Ceylan Kalin Z; Özkaya G; Aydoğan K; Saricaoğlu H; Tunali Ş
    J Immunol Res; 2015; 2015():856340. PubMed ID: 26788525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
    Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
    Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased interleukin-36γ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/Sézary syndrome.
    Otobe S; Sugaya M; Nakajima R; Oka T; Takahashi N; Kabasawa M; Miyagaki T; Asano Y; Sato S
    J Dermatol; 2018 Apr; 45(4):468-471. PubMed ID: 29314201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors.
    Illingworth A; Johansson U; Huang S; Horna P; Wang SA; Almeida J; Wolniak KL; Psarra K; Torres R; Craig FE
    Cytometry B Clin Cytom; 2021 Mar; 100(2):156-182. PubMed ID: 33112044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardized approach.
    Vermeer MH; Moins-Teisserenc H; Bagot M; Quaglino P; Whittaker S
    Br J Dermatol; 2022 Jul; 187(1):21-28. PubMed ID: 35157307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion.
    Scala E; Russo G; Cadoni S; Narducci MG; Girardelli CR; De Pità O; Puddu P
    J Invest Dermatol; 1999 Oct; 113(4):622-7. PubMed ID: 10504451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early diagnosis of mycosis fungoides and Sézary's syndrome by morphometric analysis of lymphoid cells in the skin.
    Meijer CJ; van der Loo EM; van Vloten WA; van der Velde EA; Scheffer E; Cornelisse CJ
    Cancer; 1980 Jun; 45(11):2864-71. PubMed ID: 6966534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome.
    Lima M; Almeida J; dos Anjos Teixeira M; Queiros ML; Santos AH; Fonseca S; Balanzategui A; Justica B; Orfao A
    Haematologica; 2003 Aug; 88(8):874-87. PubMed ID: 12935975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow cytometric identification of immunophenotypically aberrant T-cell clusters on skin shave biopsy specimens from patients with mycosis fungoides.
    Horna P; Kurant D; Sokol L; Sotomayor EM; Moscinski L; Glass LF
    Am J Clin Pathol; 2015 Jun; 143(6):785-96. PubMed ID: 25972320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.